Literature DB >> 17523056

Disposition of sanguinarine in the rat.

R Vecera1, B Klejdus, P Kosina, J Orolin, M Stiborová, S Smrcek, J Vicar, Z Dvorák, J Ulrichová, V Kubán, P Anzenbacher, V Simánek.   

Abstract

Sanguinarine is an alkaloid with known antibiotic and anti-inflammatory activity and its pharmacokinetics have been studied in the rat after a single oral dose (10 mg kg(-1) body weight). Alkaloid determination in the plasma and liver was carried out by high-performance liquid chromatography-electrospray ionization mass spectrometry (HPLC/ESI-MS). The pharmacokinetic parameters (t(max), c(max), AUC(0-->t) and AUC(0-->infinity)) were determined for sanguinarine and dihydrosanguinarine, the major components detected in plasma. The first step in sanguinarine metabolism in the rat was the reduction of the iminium bond resulting in formation of the less toxic dihydrosanguinarine. Both compounds were completely eliminated from the plasma and liver after 24 h and not detected in urine. After a single oral dose of (3)H-sanguinarine, more than 42% of the ingested radioactivity was present in gastrointestinal tract. Benz[c]acridine, up to date the only sanguinarine metabolite referred to in the literature, was not detected in the plasma, liver or urine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17523056     DOI: 10.1080/00498250701230542

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Sanguinarine inhibits the proliferation of BGC-823 gastric cancer cells via regulating miR-96-5p/miR-29c-3p and the MAPK/JNK signaling pathway.

Authors:  Xian-Zhe Dong; Yan Song; Yu-Pan Lu; Yuan Hu; Ping Liu; Lan Zhang
Journal:  J Nat Med       Date:  2019-06-26       Impact factor: 2.343

2.  Preclinical safety evaluation of Macleaya Cordata extract: A re-assessment of general toxicity and genotoxicity properties in rodents.

Authors:  Zhen Dong; Shu-Sheng Tang; Xiao-Lan Ma; Chang-Hong Li; Zhao-Shan Tang; Zi-Hui Yang; Jian-Guo Zeng
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.